AMPE - Ampio Pharmaceuticals, Inc.
| Previous Close | 2.44 |
| Open | 2.46 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 2.38 - 2.47 |
| 52 Week Range | 0.38 - 4.95 |
| Volume | 65,898 |
| Avg. Volume | 734,400 |
| Market Cap | 207.17M |
| Beta | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.39 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- PR Newswire•7 days ago
Ampio provides a Link to New Publication on the Mechanism of Action for Ampion™
ENGLEWOOD, Colo., July 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a basic science manuscript entitled "The Anti-Inflammatory Effect of LMWF5A and N-Acetyl Kynurenine on Macrophages: Involvement of Aryl Hydrocarbon Receptor in Mechanism of Action" authored by Dr. Bar-Or and prominent clinicians has been published online in Biochemistry and Biophysics Reports. Dr. David Bar-Or, Ampio's CSO explained: "This biochemical research uncovered an important part of the mechanism of action of Ampion™ or the low molecular weight fraction of 5% human serum albumin (LMWF5A). Here, we show that Ampion significantly decreases the release of pro-inflammatory biomarkers from LPS-stimulated macrophages and that one of the known components of Ampion (N-acetyl kynurenine or NAK) also decreased these biomarkers When an inhibitor of the aryl hydrocarbon receptor (AhR) was included, the anti-inflammatory effect of Ampion was partially blocked while the effect of NAK was completely prevented.
- ACCESSWIRE•20 days ago
Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.
- PR Newswire•22 days ago
Ampio Reports New Publication on the Mechanisms of Action for Ampion™
ENGLEWOOD, Colo., June 27, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a basic science manuscript entitled "The Anti-Inflammatory Effect of LMWF5A and N-Acetyl Kynurenine on Macrophages: Involvement of Aryl Hydrocarbon Receptor in Mechanism of Action" has been accepted for publication in Biochemistry and Biophysics Reports. Dr. David Bar-Or, Ampio's CSO explained, "This biochemical research uncovered an important part of the mechanism of action of Ampion™ or the low molecular weight fraction of 5% human serum albumin (LMWF5A).
- ACCESSWIRE•24 days ago
Today's Research Reports on Stocks to Watch: bluebird and Ampio Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / bluebird shares were in the red on Friday, retreating after several days of gains after an Evercore ISI analyst upgrade the stock to "outperform" and ...
- PR Newswire•last month
Ampio Provides Scientific Update and Links to Peer Review Publications
ENGLEWOOD, Colo., June 5, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced two peer-reviewed articles on the clinical application of Ampion™ are now available online. "Peer-reviewed journals are an important part of the scientific process, which requires intensive scrutiny by other experts in the field of any manuscript submitted before publication. Ampion™ is the 'Low Molecular Weight Fraction of 5% human serum Albumin' (LMWF-5A) that is in development to treat severe osteoarthritis of the knee (OAK).
- PR Newswire•2 months ago
Ampio Updates Regulatory and IP Activities
The Company and the FDA have agreed to a July 2018 meeting to continue their discussions on the BLA submission being prepared for Ampion™ as a treatment of the signs and symptoms of severe (KL4) osteoarthritis-of-the- knee (OAK). Ampio was awarded US patent (9,956,217 B2) titled: "Treatment of Joint conditions" that provides method protection, until the year 2035, for multiple injections of Ampion™. This is supported by the fully enrolled Open-Label Extension (OLE) study for the assessment of the clinical safety for long-term treatment with Ampion (up to 5 yearly injections) that will conclude in 2019 and the completed (published) 3 injections trial (STRUT or AP-007).
- ACCESSWIRE•2 months ago
Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks
Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...
- PR Newswire•2 months ago
Ampio Updates Scientific presentations and publications on Ampion™
ENGLEWOOD, Colo., May 22, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a poster presentation on the mechanism of action of a component of Ampion™ will be presented at AAST and the most recent study of Ampion treatment of Severe Osteoarthritis of the Knee ( AP-007-B) has been accepted for publication by PSS.
- PR Newswire•2 months ago
Ampio Provides Corporate Update
During Q1, the Company received a total of $3.1 million from investor warrants and stock options being exercised. Discussions with the FDA are ongoing to address FDA questions and provide the company's responses, as the Agency encourages companies to discuss all facets of regulatory filing, including clinical results, labeling, Chemistry, Manufacturing and Controls (CMC), and other aspects of the development process prior to filing their BLA in order to reduce the possibility of receiving a Refusal to File (RTF) notification.
- PR Newswire•3 months ago
The Pivotal Trial Results on Ampion™ (AP-003-C) Was Accepted for Publication in a Peer-Reviewed Medical Journal
ENGLEWOOD, Colo., May 2, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the publication entitled: "Intra-articular injection of the anti-inflammatory compound LMWF-5A (Ampion™) in adults with severe osteoarthritis: a double-blind prospective randomized controlled multicenter safety and efficacy trial" authored by Dr. Brian Cole, MD, Kristin Salottolo MPH and Dr. David Bar-Or, MD was accepted for publication to the peer-reviewed journal "Patient Safety in Surgery".
- Simply Wall St.•3 months ago
Who Really Owns Ampio Pharmaceuticals Inc (NYSEMKT:AMPE)?
In this article, I’m going to take a look at Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Simply Wall St.•3 months ago
How Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Can Impact Your Portfolio Volatility
If you are a shareholder in Ampio Pharmaceuticals Inc’s (AMEX:AMPE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
- PR Newswire•3 months ago
Ampio Updates Regulatory, Clinical and NYSE Activities
ENGLEWOOD, Colo., April 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has begun preliminary discussions with the Food and Drug Administration on details of the Biologics License Application (BLA) submission process for Ampion™, a treatment for severe osteoarthritis-of-the-knee. Second, Nature Biotechnology, a respected journal, with a very high impact factor, has published a commentary on Ampion, our lead drug. Finally, Ampio has received a notification letter from the New York Stock Exchange confirming that Ampio is now in full compliance with their listing requirements.
- PR Newswire•4 months ago
Ampio Updates Regulatory and Clinical Activities
ENGLEWOOD, Colo., April 3, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has retained PAREXEL® (www.parexel.com/) to assist in preparing and presenting the Biologics License Application (BLA) for Ampion™ for the treatment of osteoarthritis-of-the-knee (OAK) to the FDA. Mr. Macaluso, Ampio's CEO, noted that "PAREXEL is particularly suited to assist the Company in the preparation and presentation of the BLA to the FDA because their CRO Division helped design and manage the successful pivotal Phase III clinical trial.
- PR Newswire•4 months ago
Evidence for Delay of Total Knee Replacement (TKR) for Patients with Severe Osteoarthritis of the Knee Receiving Three Intra-articular (IA) Ampion™ Injections
ENGLEWOOD, Colo. , March 26, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced partial results of a follow-up (3.4-3.7 years), double-blind, randomized, controlled trial ...
- PR Newswire•4 months ago
Ampio Pharmaceuticals Provides Corporate Update Following Conference Call
Included below are highlighted disclosures from the corporate update and filed Annual report on Form 10K. Primary endpoint achieved statistical significance when 71% of Ampion-treated patients met the OARSI responder criteria, which exceeded the historically based standard control for a meaningful treatment in severe OAK (p
- PR Newswire•4 months ago
Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST
ENGLEWOOD, Colo. , March 6, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) hosting a conference call Wednesday, March 7th at 5:00 pm EST . Participants are invited to dial in using ...
- Motley Fool•5 months ago
Here's Why Ampio Pharmaceuticals Dropped as Much as 18.8% Today
What goes up must come down.
- Simply Wall St.•5 months ago
Is Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Still A Cheap Healthcare Stock?
Ampio Pharmaceuticals Inc (AMEX:AMPE), a US$233.14M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
- Simply Wall St.•6 months ago
Is Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) CEO Salary Justified?
Mike Macaluso is the CEO of Ampio Pharmaceuticals Inc (AMEX:AMPE), which has recently grown to a market capitalization of $220.23M. Understanding how CEOs are incentivised to run and grow theirRead More...
- PR Newswire•6 months ago
Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions
ENGLEWOOD, Colo., Jan. 16, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported a heavy schedule of meetings throughout the four-day conference, predominately with significant pharmaceutical companies discussing the successful clinical results of the company's second pivotal phase III trial announced Dec. 14, 2017. The discussions also explored whether Ampion™ could provide not only relief of signs and symptoms of osteoarthritis of the knee (OAK) but also be "a disease-modifying drug" for this condition. David Bar-Or, M.D., Ampio's CSO explained: "OAK, over time, causes progressive loss of cartilage in the knee, which is one of the reasons for limited joint function and chronic pain in this condition (although cartilage has no nerve endings, sub chondral bone does).
- Simply Wall St.•6 months ago
What Does Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Ownership Structure Look Like?
In this analysis, my focus will be on developing a perspective on Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...
- PR Newswire•6 months ago
Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders
ENGLEWOOD, Colo. , Jan. 8, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces that the company will be updating potential collaborators and attending shareholders at the J.P. Morgan ...
